Ipsen first-half profits rise on flattish sales

30 August 2013

French drugmaker Ipsen (Euronext: IPN) today (August 30) reported first-half 2013 financial results with 1.2% growth in consolidated sales to 633.6 million euros ($849.3 million), a 0.9% rise year-on-year, driven by 3.0% growth in Specialty care sales to 449.4 million euros. Other revenues amounted to 30.3 million euros.

The group’s recurring adjusted operating income amounted to 132.2 million euros, or 20.9% of consolidated sales. Consolidated net profit increased 6.4% to 96.5 million euros. Recurring adjusted consolidated net profit amounted to 98.8 million euros, up 14.3%. Net cash flow from operating activities amounted to 54.5 million euros and cash and cash equivalents stood at 117.6 million euros.

Full-year forecast

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK